公开(公告)号：US20220339244A1

公开(公告)日：2022-10-27

申请号：US17648242

申请日：2022-01-18

申请人： Seattle Children's Hospital (d/b/a Seattle Children's Research Institute)

发明人： Michael A. Portman

IPC分类号： A61K38/17 ,  A61P17/00 ,  C07K16/06 ,  C07K16/24 ,  A61K31/047 ,  A61K31/7016 ,  A61K31/717 ,  A61K31/718 ,  A61K31/25 ,  A61K31/05 ,  A61K47/18 ,  A61K47/36 ,  A61K47/02 ,  A61K47/12 ,  A61K31/60 ,  A61K31/192 ,  A61K9/00 ,  A61K39/395

摘要： The present invention relates to the discovery that etanercept reduces the rate of resistance to intravenous gamma globulin (IVIG) in subjects with acute Kawasaki disease (KD). In certain embodiments, the co-administration of etanercept and IVIG more effectively treats acute KD in subjects older than 12 months than IVIG alone. In other embodiments, the co-administration of etanercept and IVIG ameliorates coronary artery dilation in high risk subjects.

公开(公告)号：US12070488B2

公开(公告)日：2024-08-27

申请号：US17648242

申请日：2022-01-18

申请人： Seattle Children's Hospital

发明人： Michael A. Portman

IPC分类号： A61K38/17 ,  A61K9/00 ,  A61K31/047 ,  A61K31/05 ,  A61K31/192 ,  A61K31/25 ,  A61K31/60 ,  A61K31/7016 ,  A61K31/717 ,  A61K31/718 ,  A61K39/395 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/36 ,  A61P17/00 ,  C07K16/06 ,  C07K16/24

CPC分类号： A61K38/1709 ,  A61K9/0019 ,  A61K31/047 ,  A61K31/05 ,  A61K31/192 ,  A61K31/25 ,  A61K31/60 ,  A61K31/7016 ,  A61K31/717 ,  A61K31/718 ,  A61K39/395 ,  A61K39/39516 ,  A61K39/3955 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183 ,  A61K47/36 ,  A61P17/00 ,  C07K16/06 ,  C07K16/241

摘要： The present invention relates to the discovery that etanercept reduces the rate of resistance to intravenous gamma globulin (IVIG) in subjects with acute Kawasaki disease (KD). In certain embodiments, the co-administration of etanercept and IVIG more effectively treats acute KD in subjects older than 12 months than IVIG alone. In other embodiments, the co-administration of etanercept and IVIG ameliorates coronary artery dilation in high risk subjects.

公开(公告)号：US11253569B2

公开(公告)日：2022-02-22

申请号：US16401698

申请日：2019-05-02

申请人： Seattle Children's Hospital

发明人： Michael A. Portman

IPC分类号： A61K38/17 ,  A61P17/00 ,  C07K16/06 ,  C07K16/24 ,  A61K39/395 ,  A61K31/047 ,  A61K31/7016 ,  A61K31/717 ,  A61K31/718 ,  A61K31/25 ,  A61K31/05 ,  A61K47/18 ,  A61K47/36 ,  A61K47/02 ,  A61K47/12 ,  A61K31/60 ,  A61K31/192 ,  A61K9/00

摘要： The present invention relates to the discovery that etanercept reduces the rate of resistance to intravenous gamma globulin (IVIG) in subjects with acute Kawasaki disease (KD). In certain embodiments, the co-administration of etanercept and IVIG more effectively treats acute KD in subjects older than 12 months than IVIG alone. In other embodiments, the co-administration of etanercept and IVIG ameliorates coronary artery dilation in high risk subjects.

公开(公告)号：US20190336573A1

公开(公告)日：2019-11-07

申请号：US16401698

申请日：2019-05-02

申请人： Seattle Children's Hospital (d/b/a Seattle Children's Research Institute)

发明人： Michael A. Portman

IPC分类号： A61K38/17 ,  A61K9/00 ,  C07K16/06 ,  C07K16/24 ,  A61K31/047 ,  A61K31/7016 ,  A61K31/717 ,  A61K31/718 ,  A61K31/25 ,  A61K31/05 ,  A61K47/18 ,  A61K47/36 ,  A61K47/02 ,  A61K47/12 ,  A61K31/60 ,  A61K31/192 ,  A61P17/00

摘要： The present invention relates to the discovery that etanercept reduces the rate of resistance to intravenous gamma globulin (IVIG) in subjects with acute Kawasaki disease (KD). In certain embodiments, the co-administration of etanercept and IVIG more effectively treats acute KD in subjects older than 12 months than IVIG alone. In other embodiments, the co-administration of etanercept and IVIG ameliorates coronary artery dilation in high risk subjects.